Clear Cell Renal Cell Carcinoma clinical trials

Explore recruiting clear cell renal cell carcinoma clinical trials.

Recruiting clear cell renal cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Clear Cell Renal Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

Italy, Spain, Hungary, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Belgium, France, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy

Italy, Spain, Finland, Ireland, Poland, Romania +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Italy, Spain, Romania, Germany, Netherlands, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy

Poland, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Clear Cell Renal Cell Carcinoma trials by city

Clear Cell Renal Cell Carcinoma in Toronto Clear Cell Renal Cell Carcinoma in Vancouver Clear Cell Renal Cell Carcinoma in Montreal Clear Cell Renal Cell Carcinoma in Calgary Clear Cell Renal Cell Carcinoma in Edmonton Clear Cell Renal Cell Carcinoma in Ottawa Clear Cell Renal Cell Carcinoma in Winnipeg Clear Cell Renal Cell Carcinoma in Quebec City Clear Cell Renal Cell Carcinoma in Hamilton Clear Cell Renal Cell Carcinoma in Kitchener Clear Cell Renal Cell Carcinoma in London Clear Cell Renal Cell Carcinoma in Halifax Clear Cell Renal Cell Carcinoma in New York Clear Cell Renal Cell Carcinoma in Los Angeles Clear Cell Renal Cell Carcinoma in Chicago Clear Cell Renal Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease